Cargando…

Review of frovatriptan in the treatment of migraine

Triptans are recommended for the acute treatment of moderate to severe migraine or failure to respond to other acute migraine treatments. Seven triptans are available providing a wide range of choices. These triptans are more similar than dissimilar but patients do note differences in effectiveness...

Descripción completa

Detalles Bibliográficos
Autor principal: Kelman, Leslie
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515913/
https://www.ncbi.nlm.nih.gov/pubmed/18728819
_version_ 1782158453882486784
author Kelman, Leslie
author_facet Kelman, Leslie
author_sort Kelman, Leslie
collection PubMed
description Triptans are recommended for the acute treatment of moderate to severe migraine or failure to respond to other acute migraine treatments. Seven triptans are available providing a wide range of choices. These triptans are more similar than dissimilar but patients do note differences in effectiveness and in tolerance. Also migraine situations may differ from attack to attack, providing the opportunity to exploit the uniqueness of a particular triptan. Frovatriptan has a uniquely long-half life, five times that of other triptans. This provides the opportunity to use frovatriptan in mini-prophylaxis such as in menstrual-related migraine and other situations, as well as use in long-lasting or recurrent migraine.
format Text
id pubmed-2515913
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-25159132008-08-26 Review of frovatriptan in the treatment of migraine Kelman, Leslie Neuropsychiatr Dis Treat Expert Opinion Triptans are recommended for the acute treatment of moderate to severe migraine or failure to respond to other acute migraine treatments. Seven triptans are available providing a wide range of choices. These triptans are more similar than dissimilar but patients do note differences in effectiveness and in tolerance. Also migraine situations may differ from attack to attack, providing the opportunity to exploit the uniqueness of a particular triptan. Frovatriptan has a uniquely long-half life, five times that of other triptans. This provides the opportunity to use frovatriptan in mini-prophylaxis such as in menstrual-related migraine and other situations, as well as use in long-lasting or recurrent migraine. Dove Medical Press 2008-02 2008-02 /pmc/articles/PMC2515913/ /pubmed/18728819 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Expert Opinion
Kelman, Leslie
Review of frovatriptan in the treatment of migraine
title Review of frovatriptan in the treatment of migraine
title_full Review of frovatriptan in the treatment of migraine
title_fullStr Review of frovatriptan in the treatment of migraine
title_full_unstemmed Review of frovatriptan in the treatment of migraine
title_short Review of frovatriptan in the treatment of migraine
title_sort review of frovatriptan in the treatment of migraine
topic Expert Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515913/
https://www.ncbi.nlm.nih.gov/pubmed/18728819
work_keys_str_mv AT kelmanleslie reviewoffrovatriptaninthetreatmentofmigraine